Prevalence of Alzheimer's Disease and Parkinson's Disease in China: An Updated Systematical Analysis

Abstract

Background: Alzheimer's disease (AD) and Parkinson's disease (PD) are two major neurodegenerative diseases worldwide. Demographic aging is in rapid progress in China. Up-to-date estimates of AD and PD prevalence have not been provided.Methods: Studies that reported the prevalence of AD and PD in China were identified via a systematic database search from 1985 to 2018. Meta-analysis, local polynomial regression and autoregressive integrated moving average model were used for analyses.Results: A total of 99 studies were included in the study with populations of 385,312 and 227,228, respectively for AD and PD. The overall prevalence of AD and PD following age standardization was 3.20% [95% confidence interval (CI) = 3.17–3.23] and 1.06% (95% CI = 1.02–1.10), respectively in individuals over 60 years old. The rates increased drastically for every 10-years increment of age. The yearly prevalence of AD was predicted to increase from 3.81 to 6.17% in the next 5 years. Significant differences were observed between genders [male to female odds ratio (OR) for AD = 0.57, 95% CI = 0.51–0.64; OR for PD = 1.25, 95% CI = 1.06–1.46], and between education levels (Illiterate to non-illiterate OR for AD = 2.99, 95% CI = 2.38–3.75), but not between urban and rural settings.Conclusion: Our results provide an updated insight into the epidemiology of AD and PD in China and their associated rates and ratios. The findings may facilitate China policy makers and health professionals mitigate the related health issues.

Roles and Mechanisms of Gut Microbiota in Patients With Alzheimer’s Disease

“…The annual total costs are predicted to reach United States $507.49 billion in 2030 and United States $1.89 trillion in 2050 (Jia et al, 2018). Taken together, the above statistics indicate that AD not only affects morbidity or mortality but also affects the socioeconomic and health care burden in China (Jia et al, 2018;Cui et al, 2020). Although tremendous efforts have been made to treat AD, no efficient disease-modifying therapeutics are available, partially because of the limited understanding of the disease pathogenesis.…”

Targeting Oxidative Stress: Novel Coumarin-Based Inverse Agonists of GPR55

“…However, treatment of neurological and psychiatric diseases still focuses on symptomatic relief without targeting the underlying causal pathological molecular mechanisms. With an aging demography and rising incidences of AD [4] and PD [5], adequate and causal treatment with mild side-effects gains even more importance. Therefore, evaluating the role of different receptors and pathways in the homeostasis of oxidative stress in the central nervous system (CNS) might offer new opportunities in the therapy of neurological and psychiatric diseases.…”

A network pharmacology approach to uncover the key ingredients in Ginkgo Folium and their anti-Alzheimer’s disease mechanisms

“…Alzheimer’s disease (AD) is a complex and progressive neurodegenerative disorder that is considered the most common type of dementia [ 1 ]. In China, it was reported that 3.2% of people aged ≥ 60 years old were AD patients in 2018 [ 2 ]. With the rapid increase in the aging population, the yearly prevalence of AD has been predicted to increase to 5.35% in 2021 [ 2 ].…”

“…In China, it was reported that 3.2% of people aged ≥ 60 years old were AD patients in 2018 [ 2 ]. With the rapid increase in the aging population, the yearly prevalence of AD has been predicted to increase to 5.35% in 2021 [ 2 ]. The etiology of AD has not been fully deciphered.…”